Objective: Melatonin synthesis and secretion are partly modulated by estrogen and progesterone. Changes in melatonin concentrations, possibly related to the menopausal transition, may be associated with climacteric mood, sleep, and vasomotor symptoms. The aims of this study were to compare the serum concentrations of melatonin in perimenopausal and postmenopausal women and to evaluate melatonin's influence on mood, sleep, vasomotor symptoms, and quality of life.
M elatonin is a hormone produced primarily by the pineal gland, retina, skin, and gastrointestinal tract. 1 The synthesis and secretion of melatonin follow a circadian rhythm and are indirectly regulated by the light/dark cycle, with light having an inhibitory effect and with darkness having a stimulatory effect. 2 Based on animal and human studies, estrogen and, to a lesser extent, progesterone 3<6 contribute to the direct and indirect modulations of melatonin synthesis and secretion. In addition, melatonin concentration is influenced by the administration of gonadotropin-releasing hormone agonists 7, 8 ; in general, circulating melatonin concentrations seem to be high when endogenous estrogen levels are low, such as in women using oral contraception. 9 Reciprocally, it has been suggested that melatonin exerts a regulatory 10 Vmostly inhibitoryVeffect on reproduction, probably by down-regulating the hypothalamic-pituitaryovarian axis and by modulating estrogen synthesis in peripheral tissues 11 such as the breast, muscles, and adipose tissues. For instance, Voordouw et al 12 found reduced ovarian function and decreased luteinizing hormone, estrogen, and progesterone levels after a 4-month melatonin (or melatonin-progestin combinations) administration in adult women. Elevated levels of plasma/serum nocturnal melatonin (concentration, area under the curve [AUC], and peak amplitude) have also been associated with reproductive malfunctions 13 such as amenorrhea in women 7, 14 and hypogonadism in men. 15 Although peak serum melatonin concentrations and the total amount of urinary melatonin decrease physiologically with age in both men and women, 16, 17 probably owing to pineal aging, it is possible that mean nocturnal melatonin concentrations, melatonin peak time, amplitude of melatonin secretion, and duration of melatonin secretion in women vary during the menopausal transition in relation to changes in gonadal hormone levels. However, the literature on this issue is sparse and inconsistent. 18<20 Because of this possible reciprocal relationship between melatonin and gonadal hormones and because long-term administration of melatonin was found to partly improve quality of life (with regard to the physical domain) in perimenopausal women, 21 we hypothesize that melatonin may contribute to the mitigation of other symptoms associated with perimenopausal hormonal fluctuations. Among others, depressive and anxiety symptoms and disorders are common during perimenopause. 22<24 Impaired sleep quality is also common during the menopausal transition and in postmenopause. 25<29 Melatonin is known to influence mood and sleep. In fact, even with some inconsistencies, melatonin secretion seems to be lower in individuals with depression, 30<35 and melatonin or melatonin receptor agonists have antidepressant, anxiolytic, and sleep-promoting effects. 36<39 It is therefore plausible that changes in melatonin concentrations related to both aging and transition to menopause may at least partly explain the depressive, anxiety, and sleep symptoms, as well as the climacteric vasomotor symptoms, typically experienced by women during perimenopause and postmenopause.
Given the general lack of data on the association between melatonin concentration/secretion pattern and transition to menopause, the aim of this work was to describe melatonin levels in perimenopausal and postmenopausal women. We hypothesized that postmenopausal women have lower mean nighttime serum melatonin concentrations, lower melatonin exposure levels, and shorter duration of nighttime secretion than perimenopausal women. Our further aim was to evaluate the relationship between melatonin levels and depressive, anxiety, sleep, and vasomotor symptoms, as well as quality of life, in perimenopausal and postmenopausal women. We hypothesized that low melatonin concentrations, low exposure levels, and shorter duration of secretion associate with more symptoms, especially in postmenopausal women.
METHODS
The current study was part of a larger survey evaluating the effects of menopause on sleep and cognition. The women were recruited through advertisements in local newspapers in Turku, Finland; 17 of them were perimenopausal (aged 43-51 y), and 18 of them were postmenopausal (aged 58-71 y).
Perimenopause was defined as a serum follicle-stimulating hormone (FSH) level lower than 23 IU/L and an ongoing regular or irregular menstrual cycle. Postmenopause was determined by age (Q58 y) and at least 12 months of amenorrhea.
Exclusion criteria included the following: presence of a mental, cardiovascular (except for drug-treated balanced hypertension), endocrine (except for drug-treated balanced hyperlipidemia), pulmonary, neurological, or specific sleep disorder; malignancies; alcohol abuse; smoking; excessive caffeine intake (95 cups/d); and use of other substances known to affect the central nervous system. In addition, women with other conditions that may possibly affect sleep (eg, fibromyalgia and anemia) were excluded. All women had normal blood hemoglobin, leukocyte, thrombocyte, and serum thyrotropin levels. One perimenopausal woman and 13 postmenopausal women had previously used hormone therapy (HT), and a washout period of at least 12 months was required. Data collection and study design have already been described elsewhere. 40 After receiving oral and written information, all participants gave a written informed consent form. The study was approved by the ethics committees of Turku University Hospital and University of Turku.
The participants kept a sleep diary 3 weeks before the study and 1 week after the study to verify their sleep-wake rhythms. All women had regular sleep-wake schedules (from 10:00 PM-11:00 PM to 6:00-7:00 AM). Travel abroad and use of alcohol and caffeine were prohibited 1 week before and during the study. Coffee drinkers were provided decaffeinated beverages.
Blood samples were collected all throughout the year; in detail, 13 of 17 perimenopausal women and 10 of 18 postmenopausal women were studied during winter time (October to March). The participants spent one adaptation night (from 7:30 PM to 8:00 AM; lights off at 11:00 PM, lights on at 7:00 AM) in the sleep laboratory. On the following morning, a blood sample was taken for baseline serum FSH and estradiol (E 2 ) measurements. On the following evening, the women returned to the laboratory at 7:30 PM for baseline sleep recording (lights off at 11:00 PM, lights on at 7:00 AM), which was repeated also through the third night. During the night, only red light was allowed for illumination, if needed. Therefore, during the study period, the participants spent their time inside a building, in a dark room without windows, with strictly controlled nighttime illumination levels; this limited the possible influence of different photoperiods on different participants. The study was performed on all participants using a similar timetable, and food was provided by the sleep laboratory.
On the evening before the third night, an in-dwelling catheter was inserted into a forearm vein to permit 24-hour blood sampling at 20-minute intervals, starting from 9:00 PM. At night (from 9:00 PM to 7:00 AM), the catheter was connected to a plastic tube extending into an adjacent room; this allowed repeated blood sampling without disturbing the woman's sleep. The catheter was kept patent with a slow heparinized saline infusion. Thus, melatonin measurements were available for 20-minute-interval samples between 9:00 PM and midnight, and from 6:00 to 9:00 AM; measurements on 1-hour-interval samples were available between midnight and 6:00 AM. All perimenopausal women were examined at the beginning of their menstrual cycle (ie, follicular phase).
Blood samples were drawn into EDTA tubes and placed in a refrigerator for 20 minutes. Thereafter, they were centrifuged to separate serum, which was frozen at 70-C until assayed. The interassay coefficients of variation were 2.3% for FSH at a concentration of 44.8 IU/L and 8.5% for E 2 at a concentration of 0.18 nmol/L, and the analytical sensitivities were 0.05 IU/L and 0.05 nmol/L, respectively. For melatonin analyses, serum samples were first extracted with chloroform and assayed by radioimmunoassay using an iodinated melatonin tracer and a melatonin-specific antiserum. 41 The lowest detectable concentration with this method was 1.3 pg/mL (5.7 pmol/L), and the intra-assay and interassay coefficients of variation were from 6.7% to 9.5% and from 9.8% to 12.5%, respectively.
The following melatonin indicators were derived: (1) mean nighttime serum melatonin concentration from lights off (at 11:00 PM) to lights on (at 7:00 AM); (2) range and mean of the maximal and minimal nighttime serum melatonin concentrations (from lights off to lights on); (3) nighttime melatonin exposure level: after the interpolation of the melatonin exposure level curve, the area under the melatonin exposure curve (AUC; from lights off to lights on) was calculated for each individual, and the means, quartiles, and medians of melatonin exposure levels were calculated; (4) duration of nighttime melatonin secretion: the total amount of time (in hours) that serum melatonin levels (circulating melatonin) were 10 pg/mL or higher (10 pg/mL is the usual threshold for melatonin onset) 42,43 ; (5) melatonin peak time: the clock time of the peak of melatonin secretion; and (6) time from lights off to melatonin peak time (in hours).
Questionnaires
Current depressive symptoms were evaluated with the Beck Depression Inventory (BDI; a sum score with a range of 0-63), 44 and current anxiety level was evaluated with the State-Trait Anxiety Inventory (STAI; a sum score with a range of 20-80). 45 Insomnia (a sum score with a range of 5-25) and sleepiness (a sum score with a range of 5-25) in the past 3 months were evaluated using the Basic Nordic Sleep Questionnaire (BNSQ), 46 with lower scores referring to better sleep (ie, low levels of sleep problems and sleepiness; see Appendix 1, Supplemental Digital Content 1, http://links.lww.com/MENO/A64, which reports BNSQ questions concerning insomnia and sleepiness). In addition, the subjective sleep score (a sum score with a range of 6-20) of the preceding blood-sampling night in the laboratory was assessed in the morning by questions on sleep quality, sleep efficiency, sleep latency, number of awakenings, too early morning awakening, and morning tiredness, with lower numbers referring to better sleep or lower levels of sleep problems (see Appendix 2, Supplemental Digital Content 2, http://links.lww.com/MENO/A65, which reports questions concerning sleep in the preceding night, used to calculate the subjective sleep score). Climacteric vasomotor symptoms in the past 6 months were scored with two questions (night sweats and hot flashes). Frequency of symptoms (a sum score with a range of 2-8) was determined using a 4-point scale (1, Bseldom or never[; 2, Bapproximately once a month[; 3, Bapproximately once a week[; 4, Balmost every day[). Current quality of life (an index score with a range from j0.011 to +1) was assessed using the EuroQoL Quality of Life Questionnaire (EQ-5D) and the EQ-5D Visual Analogy Scale (VAS; a scale score with a range of 1-100). 47 The EQ-5D index was calculated through a specific algorithm that considers a weight for each dimension. 48 The questionnaires were administered on the day after the blood sampling.
Statistical analysis
After testing for normality of distribution (Kolmogorov-Smirnov test), we performed bivariate analyses to study the differences between perimenopausal and postmenopausal women, using Student's t test for a comparison of means. P G 0.05 was considered significant. The mean, maximal, and minimal nighttime serum melatonin concentrations; the mean nighttime melatonin exposure level; the duration of nighttime melatonin secretion; and the melatonin peak time were compared in perimenopausal and postmenopausal women using t test and Wilcoxon rank sum test.
Bivariate Pearson correlation analyses of nighttime serum melatonin concentrations, melatonin exposure level, duration of nighttime melatonin secretion, and time from lights off to melatonin peak, versus independent variables, including FSH level, E 2 level, body mass index (BMI), BDI score, STAI score, BNSQ insomnia score, BNSQ sleepiness score, subjective sleep score, climacteric vasomotor symptom score, and quality of life (EQ-5D index and EQ-5D VAS), were performed separately in perimenopausal and postmenopausal women. Interaction analyses were performed to test the associations between nighttime melatonin exposure (AUC) and, alternatively, each of the independent variables that differed (or tended to differ) between perimenopausal and postmenopausal women (ie, FSH level, E 2 level, BMI, BDI score, BNSQ insomnia score, and climacteric vasomotor score). Menopause status was entered in each model as a controlling variable. Statistical analyses were performed using SPSS/PASW version 18.0 (SPSS Inc, Chicago, IL) and the R program. 49 
RESULTS
Basic characteristics of the participants are described in Table 1 . Perimenopausal women were younger, had lower FSH levels, and had higher E 2 levels than postmenopausal women. In addition, perimenopausal women had lower BMI and less climacteric vasomotor symptoms. A tendency toward lower BDI and BNSQ insomnia scores was found in perimenopausal women. No differences in STAI anxiety score, BNSQ sleepiness score, subjective sleep score, or quality of life (EQ-5D index or EQ-5D VAS) were found.
Data on melatonin levels were available for 17 perimenopausal women and 17 postmenopausal women (missing data on one postmenopausal woman). Melatonin indicators in perimenopausal and postmenopausal women are reported in Table 2 . Mean, maximal, and minimal nighttime serum melatonin concentrations, as well as mean nighttime melatonin exposure level (AUC), were lower in postmenopausal women than in perimenopausal women ( Table 2 , Fig. 1 ). Although the melatonin peak time did not differ between the two groups, the duration of nighttime melatonin secretion (serum levels Q10 pg/mL; 43.1 pmol/L) approached the significant level for a longer duration in perimenopausal women compared with postmenopausal women (6 h 47 min vs 6 h 22 min, respectively; P = 0.058).
Mean nighttime melatonin concentration and age did not correlate. Furthermore, mean nighttime serum melatonin concentration did not correlate with FSH level, E 2 level, BMI, BDI score, STAI score, BNSQ insomnia score, BNSQ sleepiness score, subjective sleep in the preceding night, climacteric vasomotor score, or quality of life (EQ-5D index score and EQ-5D VAS) in either perimenopausal or postmenopausal women. No correlations were found between nighttime melatonin exposure level (AUC) and any of the independent variables in either perimenopausal or postmenopausal women. In the perimenopausal group, the time from lights off to melatonin peak correlated with STAI scores (r = 0.55, P = 0.022; ie, the later is the melatonin peak, the higher is the anxiety level). In addition, the duration of nighttime melatonin secretion (serum levels Q10 pg/mL; 43.1 pmol/L) correlated with EQ-5D VAS scores (r = 0.74, P G 0.001; ie, the longer is the duration of nighttime melatonin secretion, the better is the quality of life). No correlations were found in the postmenopausal group.
In interaction analyses, no association was found between nighttime melatonin exposure level (AUC) and FSH level, E 2 level, BMI, BDI score, BNSQ insomnia score, or climacteric vasomotor score after controlling for menopause status.
DISCUSSION
We are among the first to observeVbased on the results of serial blood drawsVthat postmenopausal women had reduced nighttime melatonin concentrations at each time point compared with perimenopausal women. However, the nighttime pattern of the rise and fall in melatonin levels, including the melatonin peak time, was similar for both groups. The nighttime duration of melatonin secretion (circulating melatonin concentrations Q10 pg/mL)Valthough not reaching statistical significanceVwas longer in perimenopausal women. Postmenopausal women had more depressive, insomnia, and climacteric vasomotor symptoms than perimenopausal women, but there was no evidence that these symptoms were related to melatonin levels for either group. Our findings of lower nighttime melatonin concentrations in postmenopausal women may be a reflection of the wellknown age-related decrease in melatonin levels, 16, 17 where the transition to menopause may itself be considered a dimension of aging, specifically of the hypothalamus-pituitary-ovarian system. In this respect, it is possible that menopause-related hormonal alterations, or the accompanying mood, sleep, and vasomotor symptoms, may modulate melatonin activity, for example, by accelerating its reduction. On the other hand, it is also possible that the age-related changes in melatoninV whether or not attributable to the hypothalamus-pituitaryovarian-axisYrelated hormone changesVthemselves contribute to the modulation of ovarian hormone fluctuations or to menopause-associated mood, sleep, and vasomotor symptoms.
To date, only a few studies have focused on this issue. In the study by Okatani et al, 20 nighttime serum melatonin concentration (measured via 2-h-interval samples between 8:00 PM and 8:00 AM) was higher in the oldest premenopausal women (aged 46-50 y, ie, probably perimenopausal) than in younger premenopausal women with or without oophorectomy. In addition, they found that nocturnal melatonin concentration and secretion decreased steeply in the first 15 years since the beginning of menopause and continued to decrease more gradually thereafter. In that study, reproductive state was determined based on menstrual records. Vakkuri et al 19 studied 77 women aged 30 to 75 years, dividing them into premenopausal and postmenopausal groups based on their menstrual records and thereafter into six further age groups. Nocturnal (8:00 PM-8:00 AM) urinary excretion of melatonin and morning (9:00 AM) serum melatonin were measured. Urinary melatonin levels were found to decline during the menopausal transitionVmost significantly in women aged 40 to 44 years, followed by women older than 50 years; serum morning melatonin levels also tended to be lower in women 60 years or older compared with women younger than 40 years. Considering the different age ranges of the participants and the different melatonin samplings (nocturnal urinary and morning serum samples in the study by Vakkuri et al 19 vs serial nocturnal serum samples in our current work), these results are in line with our findings of decreased melatonin concentrations in postmenopause. Because the drop in melatonin levels was most notable far before menopause age, they concluded that it could be permissively linked to the initiation of menopause. Frequently, changes in hypothalamicpituitary-ovarian function start several years before the actual cessation of menstrual periods (ie, at the age when the drop in melatonin level was more evident). Furthermore, Vakkuri et al 19 reported a negative correlation between urinary melatonin and serum FSH.
Fernandez et al 18 found the lowest morning serum (but not urinary) melatonin levels in postmenopausal women. Moreover, they found no correlation between melatonin and FSH, E 2 , or progesterone levels during the perimenopausal period, but a negative correlation between FSH and melatonin levels in postmenopausal women. We did not find any association between melatonin and FSH or E 2 levels in either perimenopausal or postmenopausal women. A plausible reason for the lack of such correlation was a considerable interindividual variation in melatonin secretion in our study. However, the fact that we used the mean of repeated nocturnal serum samplesVinstead of an overnight urinary sample as in the study by Vakkuri et al 19 or a single morning serum sample as in the study by Fernandez et al 18 Vmay not be ignored. Even though urinary melatonin (or its metabolite) sampling technique is among the most practical techniques for the assessment of melatonin secretion, given its limited possibility of repeated samples, it may lack precision. Saliva sampling is also a practical and reliable technique that allows repeated samples; however, it can hardly be used for overnight assessment. On the contrary, repeated blood samples can be more easily taken at frequent intervals during the night without or with limited sleep disruption. In addition, melatonin levels are higher in plasma than in saliva, thus implying better resolution and sensitivity. In detail, overnight blood sampling at frequent intervals seems to be the most informative technique for assessing melatonin profile. 50 Our results also suggest that the nighttime pattern of the rise and fall in melatonin levels, including the melatonin peak time, does not significantly differ between perimenopausal and postmenopausal women. This finding is in contrast with an earlier report of Walters et al 51 on the advanced phase of melatonin secretion in postmenopausal versus premenopausal women during one-night sleep deprivation. However, even though melatonin onset in the same study was found to precede the onset of subjective sleepiness equally in premenopausal and postmenopausal women, the time between melatonin onset and sleepiness was longer in postmenopausal women than in premenopausal women. 51 Possible explanations for these different outcomes include the different study designs because Walters et al 51 Melatonin concentration/secretion pattern seemed not to be related to climacteric vasomotor symptoms or BMI in either perimenopausal or postmenopausal women. As expected, postmenopausal women had more climacteric vasomotor symptoms than perimenopausal women. They also had higher BMI, which is known to increase with the transition to menopause, even with small differences by menopause type. 52 It is possible that, besides other known factors such as changes in estrogen and FSH levels, menopause-and age-related changes in melatonin levels also contribute to these symptoms and body changes in postmenopausal women. A recent animal study showed that administration of melatonin was more effective than estrogen therapy in reversing glycemic and lipid dysregulation and in restoring increased BMI after ovariectomy. 53 Based on another study, administration of melatonin to perimenopausal and postmenopausal women led to a tendency toward reduction in climacteric symptoms. 54 However, other studies did not support these results. 55, 56 Our correlation and interaction analyses did not find any association between melatonin and climacteric symptoms or BMI, even after controlling for the effect of menopause status.
Furthermore, melatonin concentration/secretion pattern seemed not to be related to depressive symptoms or sleep disturbances in either perimenopausal or postmenopausal women. In our sample, postmenopausal women tended to have more depressive and insomnia symptoms. Instead, anxiety and qualityof-life scores did not differ between perimenopausal and postmenopausal women. This is in line with the well-known increased risk of mood symptoms and disorders 22 and decreased sleep quality 57<60 during the menopausal transition. In early postmenopausal women (G5 y) versus late postmenopausal women (95 y), Hachul et al 61 found more depression, anxiety, and sleepiness in the latter group. In general, it has been reported that perimenopausal women and postmenopausal women, experience subjective sleep problems more than premenopausal women. 57<60 In this respect, a prospective study 62 showed that even after controlling for age and other confounding factors, women had higher odds for both moderate and severe self-reported sleep problems when transiting from premenopause to perimenopause, and even higher odds when transitioning to postmenopause. However, perhaps owing to the small sample size, correlation and interaction analyses did not detect any significant associations between melatonin and BDI or BNSQ insomnia score. Hence, these findings do not support our original hypothesis that low melatonin levels associate with depressive, anxiety, or sleep symptoms in postmenopausal women. Note that melatonin levels were associated with other parameters in the perimenopausal group: a delayed peak time was associated with a higher level of anxiety, whereas a longer duration of melatonin secretion was associated with a better quality of life. It is possible that higher levels of anxiety postponed the onset of sleep and, subsequently, the peak of melatonin secretion, whereas longer durations of melatonin secretion improved sleep quality and, subsequently, quality of life.
This study was the first one to use repeated serum sampling technique to evaluate the interrelationship of melatonin secretion and menopause status. This seems to be the best technique as far as the assessment of melatonin phase, duration, and amplitude is concerned, particularly when frequent (20-30 min) samples are provided. 50 Even if the study was not carried out under constant routine conditions, which would have been the most appropriate technique, the high-frequency collection of serum samples under strictly controlled sleep laboratory conditions nevertheless ensured the good quality of the samples for monitoring the pattern of melatonin concentrations. In addition, several confounding factors, such as irregular sleep-wake schedules, use of HT and other medications, smoking, and use of alcohol or drugs, were effectively ruled out by the accurate exclusion criteria.
The main limitation of our study is the rather small sample size in the context of a convenience sampling design. This, along with the elevated interindividual variability in melatonin levels, may partly explain the absence of any significant correlation between melatonin and FSH or E 2 levels, or most of the mood and sleep symptoms. However, the sample size was comparable with that of other studies in the field; even with this limited sample size, significant differences in melatonin levels were detected. The study was carried out in a healthy population, preventing the generalization of the results to populations with common diseases. Furthermore, some of the women in the perimenopausal group had regular menstruation, categorizing them as premenopausal. In addition, notice that mood, sleep, and climacteric symptoms and quality of life were retrospectively assessed with self-reported questionnaires that covered different time frames of recall (ranging from current quality of life, depressive and anxiety symptoms to climacteric symptoms in the past 6 mo)Va potential weakness in the measurement of self-reported data. However, the reliability and validity of most of these instruments have been tested and found to be reliable. 46, 63, 64 Melatonin sampling took place throughout the year, probably influencing the results. However, during the visit in the sleep laboratory, the participants spent their time inside the building, and nighttime illumination levels were strictly controlled. Finally, the cross-sectional design of the study did not allow any causal conclusions.
CONCLUSIONS
Our results confirm lower nighttime serum melatonin concentrations and exposure levels in postmenopausal women compared with perimenopausal women, with no difference in melatonin peak time. There is also a tendency toward a longer duration of melatonin secretion in perimenopausal women. Further research with prospective follow-up studies during the menopausal transition is needed to better understand the nature of these differences. Changes in melatonin levels are not related to mood, sleep quality, vasomotor symptoms, or quality of life in either perimenopause or postmenopause. This finding needs to be confirmed in larger studies. Whether the beneficial effect of HT on the alleviation of these symptoms in menopause is partly regulated via melatonin needs to be verified.
